

12 August 2024

Update on Metalyse® and Actilyse® - end of shortage period

Dear Members of the European Stroke Organisation

Boehringer has informed us about an end of the shortages of Actilyse® (alteplase) and an increase in global production for Metalyse® (tenecteplase). Background is the regulatory approval of product release by the new additional drug substance manufacturing site for Actilyse® in Vienna, Austria in July 2024.

The relocation of Actilyse's production to Vienna will provide greater production capacity for Metalyse® 25 mg at Boehringer's existing site in Biberach, Germany. This will allow Boehringer to continue its global, phased roll-out of Metalyse® 5000 U (25 mg) for acute ischemic stroke (AIS), starting in Europe in 2024. Boehringer explained that the planned production volumes of Metalyse® in the second half of 2024 will ensure a consistent, stable supply in line with its anticipated increased use as an alternative treatment to Actilyse® for the treatment of AIS and ST segment elevation myocardial infarction (STEMI).

In case you have questions, feedback, or suggestions please contact esoinfo@eso-stroke.org.

Kind regards,

Thrombolysis taskforce of the ESO Executive Committee

European Stroke Organisation (ESO)

Head Office

European Stroke Organisation

Reinacherstrasse 131
4053 Basel
Switzerland
+41 61 686 77 76
esoinfo@eso-stroke.org

Executive Committee

President

Simona Sacco
(L'Aquila, Italy)

President Elect

Urs Fischer
(Bern, Switzerland)

Past President

Peter Kelly
(Dublin, Ireland)

Vice President

Carlos Molina
(Barcelona, Spain)

Secretary General

Guillaume Turc
(Paris, France)

Treasurer

Jesse Dawson
(Glasgow, Scotland)

Members at Large

Francesca Romana Pezzella
(Rome, Italy)

Silke Walter
(Saarbrücken, Germany)